bevacizumab + lomustine

Bevacizumab + lomustine is a combination therapy consisting of two distinct anticancer agents used primarily in the treatment of progressive or recurrent glioblastoma. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis, which is critical for tumor blood supply. Lomustine is an alkylating agent from the nitrosourea class that crosslinks DNA and RNA, leading to cytotoxicity in rapidly dividing tumor cells. The combination has been evaluated in multiple clinical trials for patients with glioblastoma who have progressed after standard chemoradiation, with evidence suggesting improved progression-free survival but not overall survival compared to lomustine alone[1][5][6]. This regimen may be considered for patients who are not candidates for surgical resection or re-irradiation and can help reduce corticosteroid dependence by controlling edema[2].